College of Pharmacy, Changchun University of Chinese Medicine, Changchun, Jilin, People's Republic of China.
School of Life Science, Jilin University, Changchun, Jilin, People's Republic of China.
Int J Nanomedicine. 2021 Feb 25;16:1525-1551. doi: 10.2147/IJN.S293427. eCollection 2021.
Nanomedicines afford unique advantages in therapeutic intervention against tumors. However, conventional nanomedicines have failed to achieve the desired effect against cancers because of the presence of complicated physiological fluids and the tumor microenvironment. Stimuli-responsive drug-delivery systems have emerged as potential tools for advanced treatment of cancers. Versatile nano-carriers co-triggered by multiple stimuli in different levels of organisms (eg, extracorporeal, tumor tissue, cell, subcellular organelles) have aroused widespread interest because they can overcome sequential physiological and pathological barriers to deliver diverse therapeutic "payloads" to the desired targets. Furthermore, multiple stimuli-responsive drug-delivery systems (MSR-DDSs) offer a good platform for co-delivery of agents and reversing multidrug resistance. This review affords a comprehensive overview on the "landscape" of MSR-DDSs against tumors, highlights the design strategies of MSR-DDSs in recent years, discusses the putative advantage of oncotherapy or the obstacles that so far have hindered the clinical translation of MSR-DDSs.
纳米药物在肿瘤治疗干预方面具有独特的优势。然而，由于复杂的生理体液和肿瘤微环境的存在，传统的纳米药物未能达到预期的抗癌效果。刺激响应型药物输送系统已成为癌症先进治疗的潜在工具。在不同水平的生物体（例如体外、肿瘤组织、细胞、亚细胞细胞器）中受多种刺激共同触发的多功能纳米载体引起了广泛的关注，因为它们可以克服连续的生理和病理障碍，将各种治疗“有效载荷”递送到所需的靶标。此外，多种刺激响应型药物输送系统（MSR-DDS）为联合递药和逆转多药耐药提供了良好的平台。本文全面概述了针对肿瘤的 MSR-DDS 的“全景”，重点介绍了近年来 MSR-DDS 的设计策略，讨论了肿瘤治疗的假定优势或迄今为止阻碍 MSR-DDS 临床转化的障碍。
